Men with prostate cancer which has an intermediate risk of spreading when they are given radiotherapy are currently offered six months to three years of hormone therapy at the same time.
But AI, which looks for biological patterns in the cancer cells taken from individual men's biopsies at the point of diagnosis, can identify those who would not benefit from hormone therapy. The Daily Mail
See also:
- ArteraAI Prostate Test ArteriaAI
- Could artificial intelligence help diagnose and detect prostate cancer? Prostate Cancer UK
No comments:
Post a Comment